Keyword: Mavyret (glecaprevir and pibrentasvir)
Remember the days when AbbVie’s hep C revenues consistently fell short? Those are long gone.
The latest victory in a years-long hepatitis C patent battle between Gilead Sciences and Merck goes to Gilead.
Thanks to new competition from AbbVie, Gilead's important hep C franchise will have another rough year in 2018.
The benefits of the upcoming tax overhaul will be so great that AbbVie is planning $2.5 billion in capital projects in the U.S.
Hepatitis C dominated the discussion on Gilead's third-quarter earnings call—and it wasn’t a positive discussion.
Get set for even more competition in the hep C space as AbbVie picked up FDA approval for Mavyret.